Category Archives: Pr Newswire

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies Longer recall intervals for PRO assessments are less burdensome to clinical study participants and may improve data collection compliance SAN DIEGO, Aug. […]

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and […]

For the third consecutive year, oneZero makes the Inc. 5000 of America’s fastest-growing private companies

NEW YORK, Aug. 13, 2024 /PRNewswire/ — Today, Inc. has announced that oneZero Financial Systems, a global leader in multi-asset enterprise trading technology solutions, has reached the 2024 Inc. 5000, its annual list of the fastest-growing private companies in America. This is the third consecutive year that oneZero has made the prestigious ranking. Inc. 5000 […]

Stablecoin 2.0: The Blueprint for Global Digital Economy

Author: Raymond Yuan SINGAPORE, Aug. 13, 2024 /PRNewswire/ — Stablecoins have been in existence for over a decade, but their prominence surged after 2017 when governments worldwide started restricting or even shutting down fiat-to-Bitcoin trading channels. Since then, stablecoins have consistently acted as a crucial bridge between fiat currencies and cryptocurrencies. Today, with daily trading […]

International Youth Day 2024: Shanghai Electric Launches Onboarding Training for New Recruits with Focus on Youth Career Development

Over 700 graduates joined Shanghai Electric in the latest wave of hiring, together with the company to turn ideas into innovation that helps accelerate the smart and green transformation of the energy industry SHANGHAI, Aug. 13, 2024 /PRNewswire/ — Shanghai Electric (SEHK: 2727, SSE: 601727) recently launched a comprehensive training program tailored for over 700 newly recruited […]

HUYA Inc. Reports Second Quarter 2024 Unaudited Financial Results and Announces Share Repurchase Program Extension and Special Cash Dividend

GUANGZHOU, China, Aug. 13, 2024 /PRNewswire/ — HUYA Inc. (“Huya” or the “Company”) (NYSE: HUYA), a leading game live streaming platform in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights[1] Total net revenues for the second quarter of 2024 were RMB1,541.6 million (US$212.1 million), compared with […]

X Financial to Report Second Quarter 2024 Financial Results on August 22, 2024

SHENZHEN, China, Aug. 13, 2024 /PRNewswire/ — X Financial (NYSE: XYF) (the “Company”), a leading online personal finance company in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2024, before the open of U.S. markets on Thursday, August 22, 2024. X Financial’s management team will […]

Brand Builder Thomas Pigeon Joins Leading International Regenerative Medicine and Longevity Company Eterna Health as CMO

Thomas Pigeon Appointed as CMO of Eterna Health, Enhancing the Brand’s Reach in Regenerative Medicine MISSISSAUGA , Ontario, Aug. 12, 2024 (GLOBE NEWSWIRE) — Dr. Adeel Khan, CEO and Founder of Eterna Health today announces the appointment of Thomas Pigeon as Chief Marketing Officer “Our growth curve has been rapid and exciting. As we evolve […]

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– Recent Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrated Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints – – Strengthened Balance Sheet with $374 Million Public Offering Extending Projected Cash Runway At Least Into the Second Half of 2026 – WALTHAM, Mass., […]